Inflammatory bowel disease in adults

2021 ◽  
pp. 175573802110587
Author(s):  
Umang Qazi
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Gastrointestinal Tract ◽  
Early Diagnosis ◽  
Chronic Inflammation ◽  
Bowel Disease ◽  
Aggressive Treatment ◽  
Inflammatory Bowel ◽  
The Uk ◽  
Two Peaks

Inflammatory bowel disease (IBD) is an umbrella term used to describe a group of disorders characterised by chronic inflammation of the gastrointestinal tract, of which ulcerative colitis and Crohn’s disease are the most common. It is estimated that 500 000 people in the UK currently live with IBD. There are two peaks of incidence, the first of which is between 15 and 30 years of age, with a second smaller peak between 60 and 80 years of age. Its prevalence is ever increasing, and GPs play an important role in early diagnosis, which is the key in reducing the need for aggressive treatment.

scholarly journals Inflammatory bowel disease: a beast of burden

2011 ◽  
pp. 57-61
Author(s):  
Dawn Farrell
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Social Life ◽  
Symptom Burden ◽  
Complex Disorders ◽  
Inflammatory Bowel ◽  
The Uk

Imagine having to empty your bowel eight or ten times a day and experiencing constant panic and fear about the location of toilet facilities. Imagine experiencing constant tiredness that impacts on all aspects of your life including work, family and social life. These are just two examples of experiences commonly suffered by individuals with a condition called inflammatory bowel disease. These people are burdened with symptoms which impact on their daily lives. This research aims to provide healthcare professionals with an understanding of the extent to which individuals with inflammatory bowel disease experience symptom burden and to identify what symptoms are most problematic. Crohn’s disease and ulcerative colitis collectively termed as inflammatory bowel disease are complex disorders. In the United Kingdom, collectively Crohn’s disease and ulcerative colitis affects approximately one person in every 250 of the population. Ulcerative colitis affects up to 120,000 people in the UK, or every 1 ...

Effects of dietary tryptophan supplementation in the acetic acid-induced colitis mouse model

2018 ◽  
Vol 9 (8) ◽  
pp. 4143-4152 ◽  
Author(s):  
Shuai Chen ◽  
Meiwei Wang ◽  
Lanmei Yin ◽  
Wenkai Ren ◽  
Peng Bin ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Acetic Acid ◽  
Gastrointestinal Tract ◽  
Mouse Model ◽  
Chronic Inflammation ◽  
Bowel Disease ◽  
Intestinal Immunity ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract and is strongly associated with intestinal immunity and the microbiome.

scholarly journals Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease

2020 ◽  
Vol 14 (Supplement_2) ◽  
pp. S725-S736 ◽  
Author(s):  
Pavine L C Lefevre ◽  
Niels Vande Casteele
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Clinical Pharmacology ◽  
Gastrointestinal Tract ◽  
Bowel Disease ◽  
Kinase Inhibitors ◽  
Response To Therapy ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors ◽  
Inflammatory Bowel

Abstract Inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, are chronic inflammatory disorders of the gastrointestinal tract which are characterised, in part, by an imbalance in the production of several pro- and anti-inflammatory cytokines. Although various agents are effective for inducing and maintaining remission, approximately 20% of patients are treatment-refractory and require surgery. Parenterally administered monoclonal antibody-based biologics are associated with adverse effects resulting in treatment discontinuation and/or immunogenicity, leading to loss of response to therapy. Approximately 50% of patients who initially respond to treatment with tumour necrosis factor antagonists lose response to therapy within the 1st year of treatment. Incidence of immunogenicity tends to decrease over time, but once present can persist for years, even after treatment discontinuation. Nonimmunogenic oral small molecule therapies, including Janus kinase inhibitors, are currently being developed and have demonstrated efficacy in early phase clinical trials, which has already led to regulatory approval of tofacitinib for the treatment of patients with moderate-to-severe ulcerative colitis. Differentiation of T cells into T helper cells, which are mediators of the inflammatory response in inflammatory bowel disease, is mediated by the Janus kinase signal transducer and activator of the transcription signalling pathway. Absorption and distribution of Janus kinase inhibitors occurs at the site of action in the gastrointestinal tract, and newer compounds are being developed with limited systemic absorption, potentially reducing the risk of adverse effects. The current review describes the clinical pharmacology of approved Janus kinase inhibitors, as well as those in clinical development for the treatment of inflammatory bowel disease.

Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases

The Analyst ◽  
2022 ◽  
Author(s):  
Inês Iria ◽  
Ruben R.G. Soares ◽  
Eduardo Brás ◽  
Virginia Chu ◽  
João Gonçalves ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Gastrointestinal Tract ◽  
Chronic Inflammation ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
Biological Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is a term used to describe disorders that involve chronic inflammation in the gastrointestinal tract, affecting more than 6.8 million people worldwide.1 Biological therapy is used...

Colonic Disorders

2016 ◽  
pp. 217-228
Author(s):  
Conor G. Loftus
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Chronic Inflammation ◽  
Crohn Disease ◽  
Bowel Disease ◽  
Key Factor ◽  
Inflammatory Bowel

Inflammatory bowel disease refers to 2 disorders of unknown cause: ulcerative colitis and Crohn disease. Other possible causes of inflammation, especially infection, should be excluded before making the diagnosis of inflammatory bowel disease. The presence of chronic inflammation on biopsy is the key factor for making a diagnosis of inflammatory bowel disease.

Inflammatory Bowel Disease

2014 ◽  
pp. 734-747 ◽  
Author(s):  
Sonia Friedman
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Gastrointestinal Tract ◽  
Crohn's Disease ◽  
Inflammatory Disease ◽  
Bowel Disease ◽  
Chronic Inflammatory Disease ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that can affect any site from the mouth to the anus. The two major types of IBD are Crohn's disease (CD) and ulcerative colitis (UC).

Inflammatory bowel disease: introduction

2011 ◽  
Author(s):  
R. Mark Beattie ◽  
Anil Dhawan ◽  
John W.L. Puntis
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Family History ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
History Of ◽  
Inflammatory Bowel ◽  
The Uk

Inflammatory bowel disease 288• 25 % of inflammatory bowel disease (IBD) presents in childhood, usually as Crohn's disease or ulcerative colitis. The UK incidence is 5.2/100 000 children <16 years of age. Crohn's disease is the more common. Family history of Crohn's disease or ulcerative colitis is common. Both diseases can occur in the same family....

Inflammatory bowel disease: introduction

2018 ◽  
Author(s):  
Akshay Batra ◽  
Mark Beattie
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Genetic Predisposition ◽  
Bowel Disease ◽  
Immune Dysfunction ◽  
Complex Interaction ◽  
Indeterminate Colitis ◽  
Inflammatory Bowel ◽  
The Uk

The incidence of inflammatory bowel disease is 5.2/100,000 children less than 16 years in the UK. Crohn’s disease is the commonest form of inflammatory bowel disease followed by ulcerative colitis and indeterminate colitis. The precise aetiology of inflammatory bowel disease is unknown and reflects a complex interaction between genetic predisposition, immune dysfunction, and environmental triggers.

scholarly journals Inflammatory Bowel Disease, its Etiopathogenesis and Treatment Approaches: A Review

2021 ◽  
Vol 71 (2) ◽  
Author(s):  
Abhishek Joshi ◽  
Vrushali Gajre ◽  
Chandani Chandarana ◽  
Madhavi Ghumare ◽  
Kritika Garg ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Chronic Disease ◽  
Gastrointestinal Tract ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Diagnostic Tools ◽  
Treatment Approaches ◽  
Inflammatory Bowel

Inflammatory bowel disease is a chronic disease of the gastrointestinal tract, which is characterized by serious events of inflammation in either specifically colon (ulcerative colitis) or the whole length of the gut (Crohn’s disease). IBD affects people greatly all over the globe. It is observed that it is more prevalent in the urbanized countries. Both the etiology and pathogenesis of IBD are complex to understand. Yet many researchers have taken great efforts to figure out the etiopathogenesis. Diagnosis of IBD is also difficult thus it is required to differentiate between UC and CD. Thus, we have shed some light on the diagnostic tools too. Since the cure for IBD is difficult, treatment is the only option, hence various recent treatments are also explained with the help of this review. This review gives a brief overview of the disease also highlights the various etiopathogenesis involved.

Sign in / Sign up

Export Citation Format

Share Document